FDA Grants RMAT Designation to Cellectis Leukemia CAR-T Therapy

Key Facts

In a move highlighting the growing momentum for gene-edited therapies in treating intractable diseases, the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasme-cel. This experimental therapy targets relapsed or refractory B-cell acute lymphoblastic leukemia. The designation follows promising data from the Phase 1 BALLI-01 clinical trial and is designed to expedite the development and review of therapies intended to treat serious conditions with unmet medical needs.

This regulatory milestone places Cellectis in closer competition with biotech giants developing CAR-T therapies, such as Gilead Sciences and Novartis. Per market data, Cellectis shares surged over 11% following the announcement, as investors reacted to the prospect of a shortened regulatory path. This momentum is particularly significant for the clinical-stage biotech sector, which is anticipating several high-stakes trial readouts through the remainder of 2026.

Looking ahead, traders are monitoring liquidity in small-cap biotech stocks amid broader market shifts. According to the economic calendar, the ISM Services PMI stood at 54.5 (as of June 3, 2026), suggesting a stable environment for growth-oriented sectors. Investors should watch for upcoming clinical updates from the BALLI-01 trial as the primary catalyst for the stock's next major move.